Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis

A Multi-Center Continuation Trial for Patients Completing Study M02-518 and M02-570 of the Human Anti-TNF Monoclonal Antibody Adalimumab (D2E7) in Patients With Moderate to Severely Active Psoriatic Arthritis

The purpose of the study is to assess the long-term safety and clinical efficacy of adalimumab in treatment of moderate to severely active psoriatic arthritis

Inclusion Criteria:

• Subject completed study M02-518 or M02-570

Exclusion Criteria:

• Subject prematurely discontinued study M02-518 or M02-570

  • Female subject who is pregnant or breast-feeding or considering becoming pregnant
  • Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study